Japan stock market week to Dec 1, 2008

8 December 2008

Tokyo rebounded in the week ended December 1. The Nikkei 225 advanced 6.1%, to close at the 8,300 mark, while the Topix index rose 3.1%. The market's comeback was helped by a respite in the volatility of overseas stock markets, as well as reports of economic stimulus measures being planned or taken by major countries, including a massive 200.0-billion euro ($252.28 billion) package announced by the European Union. Meanwhile, Japanese investors were discouraged by the lack of speed from local politicians who failed to pass a second supplementary budget to finance economic stimulus programs and proposed legislature to make the government inject capital into financial institutions. The pharmaceutical index edged up 0.8%, underperforming the market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight